1. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. (September 2017) Authors: Gowin, K.; Kosiorek, H.; Dueck, A.; Mascarenhas, J.; Hoffman, R.; Reeder, C.; Camoriano, J.; Tibes, R.; Gano, K.; Palmer, J.; Mesa, R. Journal: Leukemia research Issue: Volume 60(2017:Sep.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. (March 2017) Authors: Gowin, K.; Jain, T.; Kosiorek, H.; Tibes, R.; Camoriano, J.; Palmer, J.; Mesa, R. Journal: Leukemia research Issue: Volume 54(2017:Mar.) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). (April 2017) Authors: Savona, M.R.; Garcia-Manero, G.; Roboz, G.J.; Walsh, K.J.; Kropf, P.L.; Issa, J.P.; O'Connell, C.L.; Tibes, R.; Yee, K.W.L.; Stock, W.; Lunin, S.; Berdeja, J.G.; Naim, S.; Hao, Y.; Azab, M.; Kantarjian, H. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗